Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor
Massachusetts Eye and Ear Infirmary · with University of California, San Francisco · NCT05216770
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–80 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Early Phase 1
- Target enrollment
- 165
- US sites recruiting
- 1
- Study start
- March 24, 2022
- Record last updated
- December 2, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The researchers will examine functional neural correlates that differentiate between laryngeal dystonia and voice tremor and contribute to disorder-specific pathophysiology using a cross-disciplinary approach of multimodal brain imaging.
Being studied: Brain imaging; Laryngeal sensory block with topical bupivacaine
Conditions: Laryngeal Dystonia; Spasmodic Dysphonia; Tremor
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion criteria
- Males and females of diverse racial and ethnic background;
- Age 18-80 years;
- Native English speakers;
- Right-handed;
- Normal cognitive status;
- Patients will have laryngeal dystonia or voice tremor;
- Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.
Exclusion criteria
- Subjects who are incapable of giving informed consent;
- Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;
- Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;
- Patients with any other form of dystonia;
- Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;
- Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;
- To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;
- Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;
- Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.
Recruiting US locations
Massachusetts Eye and Ear and University of California San Francisco
Boston, MA 02114
Site contact: Kristina Simonyan, MD, PhD · 617-573-6016 · Simonyan_Lab@MEEI.HARVARD.EDU
Study contacts (from the official record)
- Kristina Simonyan, MD, PhD · 617-573-6016 · simonyan_lab@meei.harvard.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+